Folks who like to stay up late are nearly 50% more likely to develop type 2 diabetes than those who go to bed earlier, a new study finds. However, it’s not just because they have an unhealthy lifestyle, according to findings presented Sunday at the annual meeting of the European Association for the Study of Diabetes in Madrid. An increased risk of type 2 diabetes among night owls remained even after researchers accounted for other unhealthy lifestyle factors like poor diet, lack of exercise, drinking, smoking and poor sleep, researchers said. “A likely explanation is that the circadian rhythm or body clock in late chronotypes is out of sync with the work and social schedules followed by society,” said lead investigator Jeroen van der Velde, a postdoctoral researcher with Leiden University Medical Center in the Netherlands. “This can lead to circadian misalignment, which we know can lead to metabolic disturbances and ultimately type 2 diabetes.” For the study, researchers analyzed health data on more than 5,000 people participating in an ongoing study on the influence of body fat on disease. The data included typical bed and waking times for each person, as well as lifestyle factors that could increase a person’s risk of diabetes, researchers said. “Previous studies have indicated that a late chronotype — preferring to go to bed late and wake up later… read on > read on >
All Lifestyle:
Exposure to PFAS ‘Forever Chemicals’ in Pregnancy Could Boost Long-Term Obesity Risk
PFAS “forever chemicals” could cause pregnant women to experience long-term weight gain, increasing their risk of obesity in middle age, a new study warns. Women with higher levels of PFAS in their blood during early pregnancy weighed more at the age of 50 than those with low levels, researchers reported Sept. 5 in the Journal of Clinical Endocrinology & Metabolism. These women also carried more body fat at age 50, potentially making them more susceptible to obesity and heart problems later in life, researchers found. “Our study supports the idea that pregnancy may be a sensitive period of PFAS exposure as it may be associated with long-term weight gain and subsequent adverse cardio-metabolic health outcomes in women,” said lead investigator Jordan Burdeau, a graduate research assistant with the Harvard T.H. Chan School of Public Health in Boston. “Our findings may improve understanding of the effects of PFAS on cardio-metabolic health during pregnancy, which in turn may improve early prevention or detection of adverse cardio-metabolic health outcomes in women,” Burdeau added in a journal news release. Per- and polyfluoroalkyl substances (PFAS) can be found in 99% of Americans, according to the Environmental Working Group. There are thousands of different PFAS chemicals, the Environmental Protection Agency says. They can be found in drinking water as well as a wide range of consumer products including paper fast food… read on > read on >
Brain’s Wiring May Trigger Depression in Some People
A distinct brain pattern appears to make some people more likely to develop depression, a new study indicates. “Deep” functional MRI brain scans revealed that a brain feature called the salience network is nearly twice as large in people with depression than in those without the condition, researchers reported Sept. 4 in the journal Nature. The salience network is a group of brain regions thought to be involved in reward processing and focusing attention, researchers said. “Having a larger salience network appears to increase the risk for depression—the effect is an order of magnitude larger than what we usually see in fMRI studies,” said senior researcher Dr. Conor Liston, a professor of psychiatry and neuroscience at Weill Cornell Medicine in New York. Functional MRI scans identify patterns of activity in the brain by measuring changes in blood flow. Researchers recruited six people with major depression to undergo repeated fMRI brain scans, and compared their results to those from 37 healthy people. On average, the depression patients had salience networks that occupied 73% more brain surface compared to those of the control group. The salience network “being implicated in depression kind of makes sense, because one of the main deficits in depression is anhedonia, which is the inability to feel pleasure and enjoy everyday activities,” said lead researcher Dr. Charles Lynch, an assistant professor of neuroscience… read on > read on >
U.S. Youth Vaping Drops to Lowest Level in a Decade
Just 5.9% of American middle and high school students now vape, a big drop from the 7.7% who did so a year ago, new government data shows. Put another way, about 1.6 million youth now say they used e-cigarettes at least once over the past month, compared to 2.1 million in 2023. Among those who say they vape, 23.6% said they do it on a daily basis. It was high school kids who drove the change, according to the National Youth Tobacco Survey (NYTS), with middle schoolers still vaping at rates roughly similar to a year ago. Still, any reduction in vaping is welcome, said Brian King, director of the U.S. Food and Drug Administration’s Center for Tobacco Products. “The continued decline in e-cigarette use among our nation’s youth is a monumental public health win,” King said in an agency news release. Yolanda Richardson, president of the Campaign for Tobacco-Free Kids, agreed that the new numbers are encouraging, but warned that the vaping and tobacco industry isn’t through with the nation’s kids yet. “Youth e-cigarette use has fallen sharply, sparing many young people from the severe nicotine addiction and other health consequences that can result from e-cigarette use,” she said in a statement. “Despite this progress, youth e-cigarette use remains a serious public health problem in the United States, and the industry remains relentless in… read on > read on >
Amid Shortages, U.S. Allows Expanded Production of ADHD Drug Vyvanse
The maker of the ADHD drug Vyvanse has been given approval by the U.S. Drug Enforcement Administration to make more of the medication as a shortage of the critical drugs continues. Following a request from the U.S. Food and Drug Administration in July, the DEA said Thursday that Takeda Pharmaceuticals may now increase its production limit by 24%. “These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of lisdexamfetamine [Vyvanse] to meet legitimate patient needs both domestically and globally,” the DEA said in a notice it posted on the approval. ADHD drugs have been in short supply for years. The FDA first warned of a shortage of Teva Pharmaceutical Industries’ Adderall medication in October 2022, as the company was plagued by manufacturing delays. That prompted a spike in demand and subsequent shortage of Takeda’s Vyvanse. Why was the DEA’s approval to boost production needed? Vyvanse (lisdexamfetamine) is classified by the DEA as a schedule II controlled substance, which is applied to drugs considered to have a high likelihood of being abused, so additional prescribing safeguards are put in place. The production limit for lisdexamfetamine was increased by 13, 478 pounds (6,236 kilograms), which includes 3,434 pounds (1,558 kg) to address domestic demand and 10,313 pounds (4,678 kg) for foreign demand for finished dosage medications, according to the DEA. After Takeda lost exclusivity… read on > read on >
Marijuana Use Raises Workers’ Absenteeism Rate: Study
The stereotype of the slacker stoner might not be too far off the mark, a new study shows. People who use weed are prone to workplace absenteeism — and the more problematic the cannabis use, the more likely they are to skip work, results showed. “These findings underscore the importance of developing and implementing strategies to monitor, screen and intervene with individuals at risk for problematic cannabis use,” concluded the research team led by Dr. Kevin Yang, a psychiatric resident with the University of California, San Diego. “To address these issues, workplace prevention programs focusing on education, screening and access to treatment are imperative,” the team said in the paper, which was published recently in the American Journal of Preventive Medicine. For the study, researchers analyzed data on nearly 46,500 people gathered in 2021 and 2022 as part of the National Survey on Drug Use. Nearly 16% of full-time employed adults in the survey said they’d used weed in the past month, and almost 7% appeared to have cannabis use disorder, researchers found. People were more likely to skip work if they’d used weed in the past moth, results showed. Those who used the drug once or twice were 57% more likely to skip work than non-users, while those who used 20 to 30 days were 83% more likely to shrug off their work responsibilities,… read on > read on >
Ketamine Can Fight Depression, But Pregnant Women Face Risks
Ketamine is becoming a popular depression drug, but doctors aren’t keeping in mind the danger it can pose to a pregnancy, a new study warns. Ketamine can be very harmful to a developing fetus and should not be used during pregnancy, researchers said. But only 20% of ketamine clinics require a pregnancy test at least once prior to or during treatment, according to results published recently in the Journal of Clinical Psychiatry. Further, only 26% of clinics discuss the potential need for contraception with ketamine patients, and fewer than 15% specifically recommend or require contraception use during ketamine treatment, researchers found. That is concerning because more than 80% of clinics prescribe long-term maintenance ketamine, with nearly 70% saying patients receive care for more than six months. “These data suggest that a large population of patients could be pregnant, or could become pregnant, while receiving ketamine treatment,” said lead researcher Dr. Rachel Pacilio, a clinical assistant professor of psychiatry at the University of Michigan. “Many patients do not know that they’re pregnant in the first weeks, and animal studies of ketamine are very concerning for potential harm to the fetus during this time,” Pacilio added in a university news release. Ketamine is administered to people with depression as an IV drip or through a nasal spray. It works differently from standard antidepressants, according to the Mayo Clinic,… read on > read on >
Folks Who Cope, Adapt Do Well in Old Age: Study
People who can cope with challenges as they grow older are more likely to live longer, a new study shows. Seniors with higher levels of mental resilience are 53% less likely to die within the next 10 years than those with the lowest levels, researchers found. Even with chronic health problems or an unhealthy lifestyle, people with high mental resilience remained 46% and 38% less likely to die within 10 years than those with the least fortitude. “Resilience is often discussed in terms of protective factors, allowing adults in normal environments to maintain relative stability even in the face of highly disruptive events,” wrote the research team led by Dr. Yiqiang Zhan, an associate professor of epidemiology with the Sun Yat-Sen University School of Public Health in China. “This study is unique in establishing a statistically significant association between psychological resilience and all-cause mortality in the older and retired population, even after accounting for confounding factors,” the researchers concluded in a university news release. Good coping skills can help offset long-term chronic illnesses or disabilities in older age, they added. However, it hasn’t been clear whether the ability to cope and adapt is associated with slower aging or a lower risk of death, researchers said. To examine this, they analyzed data from more than 10,500 participants in a U.S. health and retirement study involving people 50… read on > read on >
Could Your Cellphone Be Harming Your Heart?
Your cellphone might be harming your heart, a new study warns. People who regularly use a cellphone have a higher risk of heart disease, researchers found in a large-scale study. And the more time someone spends on their phone, the greater their risk for heart problems, researchers report. Risk of heart disease was about 21% higher in people who use their phone six hours or more a week, compared with 15% higher for those on the phone four to six hours and 13% for one to three hours, results show. “We found that compared with non-regular mobile phone users, regular mobile phone users had a significantly higher risk of incident cardiovascular diseases,” said researcher Dr. Ziliang Ye, with Southern Medical University in China. For the study, researchers analyzed data from more than 444,000 participants in the long-term UK Biobank research project. The participants all reported the frequency of their cellphone use. Researchers defined regular mobile phone use as at least one call per week. The research team tracked the participants for about 12 years, looking to see if they’d been diagnosed with stroke, heart disease, heart rhythm problems or heart failure. It turned out that regular phone users did have a higher risk of heart problems, compared to non-users, and that more cellphone use increased that risk. Cellphone use can impact a person’s sleep patterns… read on > read on >
Ozempic, Wegovy Won’t Raise User’s Suicide Risk, Study Finds
The booming popularity of the weight-loss drug semaglutide has prompted increasing concerns about potential side effects from taking Ozempic or Wegovy. But a new study rules out one possible problem — using semaglutide does not increase a person’s risk of depression or suicide, researchers report. Semaglutide did not increase the risk of depression, suicidal thoughts or suicidal behavior in people without known mental health disorders, according to an analysis of data from clinical trials that led to approval of the drug. The new study reviewed data from more than 3,500 people across four major clinical trials for semaglutide. The trials were funded by Novo Nordisk, the maker of Ozempic and Wegovy. About 1% or fewer of the clinical trial participants reported suicidal thoughts or behaviors, with no differences between those taking semaglutide or a placebo, researchers reported Sept. 3 in the journal JAMA Internal Medicine. What’s more, 2.8% of those taking semaglutide developed depressive symptoms, compared with 4.1% of those taking a placebo. “It is certainly possible that individuals with overweight or obesity who take semaglutide may experience depressive symptoms or suicidal ideation or behavior, but the data suggest that persons not taking semaglutide — in the placebo group in this study — are equally likely to experience these conditions,” said researcher Gregory Brown, director of the Penn Center for the Prevention of Suicide at… read on > read on >